In an effort to combat Alzheimer's disease, Acumen Pharmaceuticals Inc. (NASDAQ: ABOS) will be hosting a conference call today to discuss the positive results from the Phase 1 INTERCEPT-AD trial of ACU193, a clinical-stage antibody therapy for early Alzheimer's disease.
The conference call will feature Acumen's leadership team, as well as renowned experts in the field such as Steven DeKosky, M.D., and Lawrence Honig, M.D., Ph.D.
ACU193 is a humanized monoclonal antibody that specifically targets toxic soluble amyloid beta oligomers (AβOs), which are believed to be the most harmful form of Aβ in Alzheimer's disease.
During the Phase 1 INTERCEPT-AD trial, the focus was on evaluating the safety and effectiveness of ACU193 in patients with early Alzheimer's disease.